Roche NimbleGen Announces Frank Pitzer as New CEO

(PresseBox) (Madison,WI,USA, ) Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY), a global leader in microarray tools for genetic discovery and analysis, announced today that Frank Pitzer has been appointed as CEO. Dr. Pitzer's extensive background and experience of over eight years at Roche will be instrumental in guiding the company through its next stage of growth. With his successful track record in several key management positions within Roche Diagnostics, he brings a wealth of organizational, commercial, and relevant operating experience in key areas impacting the genomics and life science industry today.

Dr. Pitzer most recently served as Head of Divisional Quality and Regulatory Affairs reporting directly to the CEO of Roche Diagnostics and was also an active member of the Diagnostics Executive Committee (DEC). In addition to his extensive management experience and background at Roche, Dr. Pitzer brings a broad scientific perspective having earned a PhD in Biology from Max Planck Institute for Biochemistry.

"We are extremely excited to announce Dr. Frank Pitzer as the CEO of Roche NimbleGen and look forward to expanding the company's position as a leading genomics solution provider," stated Manfred Baier, Head of Roche Applied Science. "Frank's leadership skills and extensive experience in the life science industry make him the perfect fit to guide Roche NimbleGen through the next stages of growth. His valuable insight and outstanding management experience will further entrench the company as a leading manufacturer of microarray technologies."

For more information on Roche NimbleGen, visit www.nimblegen.com

Kontakt

Roche Diagnostics Deutschland GmbH
Sandhofer Str. 116
D-68305 Mannheim
Kary Staples
Roche NimbleGen
Dr. Burkhard Ziebolz
Roche Applied Science
Head Global Communication
Claudia Fuchs
Assistant to Dr. Jochen Strack, Head of Global Finance RAS
Social Media